Frazier Life Sciences Acquisition Corp. II (NASDAQ:FLSC) Shares Shorted: Short Interest Down 85.9% in October

Frazier Life Sciences Acquisition Corp. II (NASDAQ:FLSC) was the recipient of a significant drop in short interest in the month of October. As of October 30th, there was short interest totaling 2,442 shares, a drop of 85.9% from the October 15th total of 17,259 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 35,837 shares, the days-to-cover ratio is presently 0.1 days.

Frazier Life Sciences Acquisition Corp. II Stock Up 0.4%

NASDAQ FLSC traded up $0.04 during trading on Wednesday, reaching $10.19. 24,700 shares of the company traded hands, compared to its average volume of 94,008. Frazier Life Sciences Acquisition Corp. II has a 1-year low of $10.08 and a 1-year high of $10.63.

Insider Buying and Selling

In other news, CEO Albert Cha bought 300,000 shares of Frazier Life Sciences Acquisition Corp. II stock in a transaction that occurred on Thursday, October 15th. The stock was purchased at an average cost of $10.00 per share, with a total value of $3,000,000.00. Following the completion of the transaction, the chief executive officer directly owned 300,000 shares in the company, valued at $3,000,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Analyst Ratings Changes

Separately, Wall Street Zen raised shares of Frazier Life Sciences Acquisition Corp. II to a “hold” rating in a report on Saturday, October 24th.

About Frazier Life Sciences Acquisition Corp. II

Frazier Life Sciences Acquisition Corp. II is a special purpose acquisition company (SPAC) formed to pursue a merger, asset acquisition, stock purchase, reorganization or similar business combination. Its stated focus is on businesses in the life sciences sector. As a SPAC, the company does not itself develop or sell medicines, medical devices or other products. Its role is to identify and combine with a target business, which would then operate as a public company. The company is associated with Frazier Life Sciences, the life sciences investment arm of Frazier Healthcare Partners.